Your AI-Trained Oncology Knowledge Connection!

Matthew Steven Davids, MD, MMSc

home / authors / matthew-steven-davids-md-mmsc

Articles

Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s Syndrome

July 26th 2020

The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.

Matthew Steven Davids, MD, MMSc on Venetoclax Plus R-EPOCH in Hematologic Cancers

Matthew Steven Davids, MD, MMSc

July 11th 2020

The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.

Venetoclax Plus Dose-Adjusted R-EPOCH Shows Promise for Richter’s Syndrome

Matthew Steven Davids, MD, MMSc

June 21st 2020

A multicenter phase 2 study of patients with chronic lymphocytic leukemia who developed Richter’s syndrome, presented at the 2020 ASCO Virtual Scientific Program, assessed the use of this treatment combination.

Matthew Steven Davids, MD, MMSc, Discusses a Phase II Study for Richter’s Syndrome

Matthew Steven Davids, MD, MMSc

June 12th 2020

The study evaluated venetoclax plus dose-adjusted R-EPOCH in patients with chronic lymphocytic leukemia who developed Richter’s syndrome.

Matthew Steven Davids, MD, MMSc, on Venetoclax Plus R-EPOCH to Treat Richter’s Syndrome

Matthew Steven Davids, MD, MMSc

June 1st 2020

The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter’s Syndrome.